Clairity Breast AI tool expands rollout for five year breast cancer risk

In short: Clairity Breast, an FDA-authorized AI tool, is rolling out more widely to estimate a person’s five year breast cancer risk from a routine mammogram.

What happened

Clairity Breast is software that reviews a standard screening mammogram and gives an estimate of the chance someone will be diagnosed with or develop breast cancer in the next five years. The US Food and Drug Administration authorized it in 2025 under the device name Allix5.

The key point is what it does not do. It does not detect or diagnose cancer that is already there, and it does not tell you what follow-up care you should get. Think of it like a weather forecast for risk, not a storm report (it can suggest the odds of future trouble, but it cannot confirm what is happening today).

Clairity says its system looks for patterns in the images that are linked with future risk. Unlike many traditional risk calculators, it does not require someone to type in details like family history to generate its image-based estimate.

The rollout is described as nationwide, but that does not mean every imaging center has it. The FDA authorization also has limits, because it applies to directly acquired 2D screening mammograms from specified Hologic mammography systems.

Why it matters

A risk score can help start a more informed conversation with a clinician, but it can also be misunderstood. Experts caution that a higher score is not a diagnosis and a lower score does not rule cancer out, so routine screening still matters. FDA materials also note that scores above 5% may overestimate risk, especially above 10%, and the device has not been shown to work for people with breast implants.

Source: NYTimes